Bank of America’s Gain Therapeutics GANX Stock Holding History

Bank of America’s Portfolio GANX Stock Details GANX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-3,908	Closed	-$12.6K	–	6164
2025 Q4	$12.6K	Buy	3,908 +1	+0%	+$3	﹤0.01%	6119
2025 Q3	$6.92K	Sell	3,907 -257	-6%	-$434	﹤0.01%	7264
2025 Q2	$7.5K	Buy	4,164 +62	+2%	+$115	﹤0.01%	7238
2025 Q1	$7.83K	Buy	4,102 +17	+0.4%	+$38	﹤0.01%	7157
2024 Q4	$8.82K	Buy	4,085 +501	+14%	+$1.01K	﹤0.01%	7006
2024 Q3	$6.38K	Buy	3,584 +84	+2%	+$106	﹤0.01%	6966
2024 Q2	$4.48K	Buy	3,500 +125	+4%	+$325	﹤0.01%	7032
2024 Q1	$12.7K	Buy	+3,375	New	+$14K	﹤0.01%	6837

Other funds holding GANX

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

PCM

Potomac Capital Management New York $115M AUM

Jones Financial Companies Des Peres, Missouri $208B AUM 16.12% 1-Year Est. Return

Cambridge Investment Research Advisors Fairfield, Iowa $43.3B AUM 29.3% 1-Year Est. Return

DCM

DME Capital Management New York $3.19B AUM 23.22% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

GCP

GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

VFT

Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

Bank of America's GANX Position: Q1 2026 in Review

Bank of America sold out of Gain Therapeutics (GANX) in Q1 2026, closing a stake of 3,908 shares — an estimated $12.6K sold.

Bank of America first reported a position in GANX in Q1 2024 and held it in 8 quarters. The position peaked at $12.7K in Q1 2024. 42 funds tracked by Wall St. Rank hold GANX as of Q1 2026.

Bank of America reported no remaining Gain Therapeutics position as of Q1 2026 after selling out during the quarter.
Bank of America sold 3,908 Gain Therapeutics shares in Q1 2026, an estimated $12.6K.
Bank of America first reported a position in Gain Therapeutics in Q1 2024 and held it in 8 quarters.
Bank of America's Gain Therapeutics position peaked at $12.7K in Q1 2024.
42 funds tracked by Wall St. Rank held Gain Therapeutics as of Q1 2026.

Based on Bank of America's 13F filing for Q1 2026, filed 18 May 2026.